Researchers create a strong new molecule in the fight against AIDS

June 19, 2000

Integrase inhibitor may prevent HIV from taking over healthy cells

Researchers have created a new molecule that appears to survive in cells longer than existing treatments to combat the virus that leads to AIDS, according to a new study reported in the June 21 edition of the peer-reviewed Journal of the American Chemical Society, published by the world's largest scientific society.

The new molecule, called a dinucleotide, has been created in the laboratory of Vasu Nair, Ph.D. at the University of Iowa, using complex molecular engineering techniques. No human or animal testing has been done and much more testing is necessary before the compound can become a drug, he noted.

Drugs to arrest the effects of other viral enzymes that lead to HIV are currently in clinical use to stop the infectious chemical chain reaction. The virus, however, often overcomes these drugs -- including well-known AZT -- through development of resistance. Promising preliminary lab results show that the new integrase inhibitor molecule may possess the ability to withstand the body's attempts to block its actions, said Nair, who was lead author of the study.

More than 40 million people worldwide are infected with the human immunodeficiency virus, referred to as HIV, which leads to AIDS. Current drug treatments face ongoing problems with drug resistance and toxicity, making the current study relevant to the next generation of AIDS medical treatments.

The compound is designed to stop HIV infection by preventing the virus from spreading to non-infected human cells. Called an HIV integrase inhibitor, the potential drug stops a key step that allows the virus to infect people, Nair said. The work was done in collaboration with the National Institutes of Health.

"I feel excited about this as a basic advancement in the science of inhibitors of this virus," Nair said. "Most therapeutic advances start this way, with scientific discoveries such as this."

HIV infection is a multi-step process, where the virus penetrates the body's cells and begins to replicate itself. The virus uses its own enzymes and reproduces itself through the body's own biochemistry.

An early major step involves a viral enzyme called reverse transcriptase that creates the DNA of the virus. The next step involves the HIV integrase enzyme, which allows the virus to take over normal human cells by "integrating" the viral DNA into the cells. Once integrated, the virus can reproduce itself. A subsequent third enzyme, protease, allows the virus to continue to replicate itself and spread the infection from cell to cell.

Development of a potential solution to stopping integrase, which inserts viral DNA into healthy cells, would allow doctors another chance to stop the onset of AIDS if the other drugs are unsuccessful. It is not a vaccine for the virus, but ideally it may represent another approach to combating the spread of the disease, Nair said.

"The integrase step is the most critical step in my point of view, because this is where the (viral) invasion is complete," Nair said. "From a scientific point of view, this is the step in which the real damage is done."
-end-
6/19/00 #12794

Dr. Vasu Nair, Distinguished Professor of Chemistry, Department of Chemistry, University of Iowa

The on-line version of the research paper cited above is available on the American Chemical Society's ASAP (As Soon As Publishable) Web site. Journalists desiring full access to papers at the ASAP site must submit a written request to the ACS Department of News and Information or send an e-mail to newsroom@acs.org.

The on-line version of the research paper cited above was initially published June 3 on the journal's Web site. The research was funded by the National Institutes of Health.

A nonprofit organization with a membership of 161,000 chemists and chemical engineers, the American Chemical Society publishes scientific journals and databases, convenes major research conferences, and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio. (http://www.acs.org)

American Chemical Society

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.